And yes, Valeant's stock is getting hammered

Valeant‘s stock is down around 9%, sliding on the news that investor Bill Ackman’s hedge fund, Pershing Square, is unloading its entire stake in the company.

This ends a three-year involvement with the company for Ackman. During that time, Valeant’s stock price fell from a high of about $US279 in the summer of 2015, to where it sits under $US11 today.

The company became the subject of several federal investigations, including one involving a secret pharmacy that it used to operate which is now be accused of insurance fraud.

And it was pressured to hire a new CEO while its executives were repeatedly called to Washington for Congressional hearings.

It was quite a ride.

NOW WATCH: Take a look inside the Laguna Beach vacation home Warren Buffett listed for $US11 million

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.